Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Complex III assembly factor LYRM7 (LYRM7) is a small, nuclear-encoded mitochondrial matrix protein essential for assembly of the mitochondrial respiratory chain complex III (ubiquinol-cytochrome c reductase). It acts as a dedicated chaperone for the Rieske iron-sulfur (Fe-S) protein (UQCRFS1), stabilizing and assisting its maturation and insertion into complex III. LYRM7 binds the co-chaperone HSC20, facilitating iron-sulfur cluster transfer from the main scaffold protein ISCU to UQCRFS1. Loss-of-function mutations in LYRM7 disrupt complex III assembly, resulting in severe mitochondrial complex III deficiency, which clinically manifests as varied early-onset neurometabolic disorders and leukoencephalopathy[1][2][3][4]. To date, there are no known therapeutic drugs that target LYRM7 directly; its dysfunction is primarily characterized by the loss of respiratory chain activity, rather than as a direct drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Complex III assembly factor LYRM7 (LYRM7).